Literature DB >> 28838420

Update on Therapeutic Drug Monitoring in Crohn's Disease.

Valérie Heron1, Waqqas Afif2.   

Abstract

In patients with Crohn's disease on biologic medications, the use of therapeutic drug monitoring leads to a personalized approach to optimize treatment. Using an algorithmic approach, measurement of drug concentrations and anti-drug antibodies can be used to improve treatment outcomes. Therapeutic drug concentrations and absence of antibodies are associated with improved clinical and endoscopic outcomes. In clinical practice, therapeutic drug monitoring has been shown to be clinically useful and cost-effective in patients experiencing a loss of response to treatment. This review highlights the available data on therapeutic drug monitoring in the treatment of patients with Crohn's disease on biologic medications.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-drug antibodies; Anti-tumor necrosis factor; Biologics; Crohn's disease; Drug concentrations; Inflammatory bowel disease; Therapeutic drug monitoring

Mesh:

Substances:

Year:  2017        PMID: 28838420     DOI: 10.1016/j.gtc.2017.05.014

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  3 in total

1.  [Protective effect of procyanidin B2 on intestinal barrier and against enteritis in a mouse model of trinitrobenzene sulphonic acid-induced colitis].

Authors:  Congqiao Jiang; Pingsheng Zhu; Yi Shi; Wujun Xiang; Sitang Ge; Zongbing Zhang; Lugen Zuo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-07-30

2.  ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Authors:  Gary R Lichtenstein; Edward V Loftus; Kim L Isaacs; Miguel D Regueiro; Lauren B Gerson; Bruce E Sands
Journal:  Am J Gastroenterol       Date:  2018-03-27       Impact factor: 10.864

Review 3.  Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease.

Authors:  Sophie Restellini; Waqqas Afif
Journal:  J Clin Med       Date:  2021-03-17       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.